Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 148Breast Neoplasms 117Prostatic Neoplasms 62Multiple Myeloma 57Neoplasms 56Lung Neoplasms 50Neoplasm Metastasis 44Parkinson Disease 4, Autosomal Dominant Lewy Body 36Ovarian Neoplasms 36Colorectal Neoplasms 35Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Renal Cell 27Recurrence 26Leukemia, Myeloid, Acute 26Urinary Bladder Neoplasms 25Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 23Myasthenia Gravis 22Triple Negative Breast Neoplasms 21Endometrial Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Lymphoma, Large B-Cell, Diffuse 20Lymphoma, Follicular 20Melanoma 19Nasopharyngeal Carcinoma 18Fallopian Tube Neoplasms 18Stomach Neoplasms 17Non-Muscle Invasive Bladder Neoplasms 16Brain Neoplasms 16Pancreatic Neoplasms 15

Interventions

gamma-Globulins 1Saline Solution 1Panzyga 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Agammaglobulinemia × 90 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645107 2026-04-13

EXCELL

Grifols Therapeutics LLC

Phase 3 Recruiting
386 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Bacterial Infections, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡